Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
How to buy Aurinia Pharmaceuticals stock
Learn how to easily invest in Aurinia Pharmaceuticals stock.
Aurinia Pharmaceuticals Inc is a biotechnology business based in the US. Aurinia Pharmaceuticals shares (AUPH) are listed on the NASDAQ and all prices are listed in US Dollars. Aurinia Pharmaceuticals employs 294 staff and has a trailing 12-month revenue of around 0.00.
How to buy shares in Aurinia Pharmaceuticals
- Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
- Open your brokerage account. Complete an application with your details.
- Confirm your payment details. Fund your account.
- Research the stock. Find the stock by name or ticker symbol – AUPH – and research it before deciding if it's a good investment for you.
- Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
- Check in on your investment. Optimize your portfolio by tracking your stock.
Aurinia Pharmaceuticals stock price (NASDAQ: AUPH)Use our graph to track the performance of AUPH stocks over time.
Aurinia Pharmaceuticals shares at a glance
|Latest market close||$16.26|
|52-week range||$9.72 - $33.97|
|50-day moving average||$21.81|
|200-day moving average||$17.69|
|Wall St. target price||$31.56|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-1.22|
Buy Aurinia Pharmaceuticals shares from these brokeragesCompare special offers, low fees and a wide range of types of investments among top trading platforms.
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
Is it a good time to buy Aurinia Pharmaceuticals stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Aurinia Pharmaceuticals price performance over time
|1 week (2022-01-19)||-12.30%|
|1 month (2021-12-23)||-29.46%|
|3 months (2021-10-26)||-46.43%|
|6 months (2021-07-26)||48.76%|
|1 year (2021-01-26)||-7.72%|
|2 years (2020-01-24)||-14.20%|
|3 years (2019-01-25)||165.25%|
|5 years (2017-01-26)||433.11%|
Aurinia Pharmaceuticals financials
|Revenue TTM||$72.2 million|
|Gross profit TTM||$-209,000|
|Return on assets TTM||-23.99%|
|Return on equity TTM||-44.01%|
|Market capitalisation||$2.1 billion|
TTM: trailing 12 months
Aurinia Pharmaceuticals share dividends
We're not expecting Aurinia Pharmaceuticals to pay a dividend over the next 12 months.
Have Aurinia Pharmaceuticals's shares ever split?
Aurinia Pharmaceuticals's shares were split on a 1:50 basis on 22 October 2013. So if you had owned 50 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Aurinia Pharmaceuticals shares – just the quantity. However, indirectly, the new 4900% higher share price could have impacted the market appetite for Aurinia Pharmaceuticals shares which in turn could have impacted Aurinia Pharmaceuticals's share price.
Aurinia Pharmaceuticals share price volatility
Over the last 12 months, Aurinia Pharmaceuticals's shares have ranged in value from as little as $9.72 up to $33.972. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Aurinia Pharmaceuticals's is 0.6898. This would suggest that Aurinia Pharmaceuticals's shares are less volatile than average (for this exchange).
Aurinia Pharmaceuticals overview
Aurinia Pharmaceuticals Inc. , a biopharmaceutical company, develops and commercializes therapies to treat various diseases with unmet medical need in Japan and China. The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co. , Ltd. The company is headquartered in Victoria, Canada. .
Aurinia Pharmaceuticals in the news
Netflix shares fall near pre-pandemic level as investors fear slowing subscriber growth, competition
Stocks making the biggest moves midday: Netflix, Kohl's, Wynn Resorts, General Motors and more
RBC upgrades Comcast to outperform on subscriber growth
Frequently asked questionsWhat percentage of Aurinia Pharmaceuticals is owned by insiders or institutions?
Currently 7.657% of Aurinia Pharmaceuticals shares are held by insiders and 39.793% by institutions. How many people work for Aurinia Pharmaceuticals?
Latest data suggests 294 work at Aurinia Pharmaceuticals. When does the fiscal year end for Aurinia Pharmaceuticals?
Aurinia Pharmaceuticals's fiscal year ends in December. Where is Aurinia Pharmaceuticals based?
Aurinia Pharmaceuticals's address is: 4464 Markham Street, Victoria, BC, Canada, V8Z 7X8 What is Aurinia Pharmaceuticals's ISIN number?
Aurinia Pharmaceuticals's international securities identification number is: CA05156V1022 What is Aurinia Pharmaceuticals's CUSIP number?
Aurinia Pharmaceuticals's Committee on Uniform Securities Identification Procedures number is: 05156V102
More guides on Finder
Today’s top U.S. stocks: Mechel Pao ADRs (MTL ↑8.1%), Sibanye-Stillwater Limited (SBSW ↑7.4%)
See the 10 biggest gainers on the New York Stock Exchange and Nasdaq.
How to order free at-home COVID tests today — but note, there’s a wait
Starting Jan. 18, every household can order up to four free at-home COVID-19 tests. But you’ll have to wait for them.
Today’s top U.S. stocks: Las Vegas Sands (LVS ↑15.3%), Wynn Resorts Limited (WYNN ↑9.1%)
See the 10 biggest gainers on the New York Stock Exchange and Nasdaq.
Donut savings review
Donut earns up to 10% APY, but you must have an iOS device.
Monie savings review
Monie offers 5% APY on deposits, but funds aren’t insured and the interface is buggy.
Covid test stocks
We’ve rounded up stats on some of the most popular COVID test stocks, along with information on how they compare and how to invest.
Is Berkshire Hathaway the next $1 trillion stock?
Buffett’s Berkshire Hathaway may now be on its way to becoming the next trillion-dollar company.
Tesla roars into 2022 after December drop
Record vehicle deliveries cause the Tesla stock price to move close to all-time highs.
How to buy Affinia Therapeutics (AFTX) stock when it goes public
Everything we know about the Affinia Therapeutics IPO, plus information on how to buy in.
How to buy Austin Gold (AUST) stock when it goes public
Everything we know about the Austin Gold IPO, plus information on how to buy in.
Ask an Expert